Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will be a multicenter, randomized, double-blind, placebo-controlled, multiple dose
study in which approximately 24 subjects with SCLE will be enrolled. Cohort 1 will consist of
12 subjects (6 AMG 557: 6 placebo) randomized to receive AMG 557 210 mg or matching placebo.
Cohort 2 will consist of 12 subjects (6 AMG 557: 6 placebo) randomized to receive AMG 557 140
mg or matching placebo. Enrollment of Cohort 2 (140 mg) will be initiated after enrollment of
Cohort 1 (210 mg) is completed.